2-((2-ethyl-2,3-dihydrobenzofuran-2-yl))-2-imidazoline,
efaroxan,
efaroxan hydrochloride,
Efaroxan hydrochloride,
89197-00-2,
RX 821037A,
2-(2-Ethyl-2,3-dihydrobenzofuran-2-yl)-4,5-dihydro-1H-imidazole hydrochloride,
MFCD00069270,
2-(2-ETHYL-2,3-DIHYDROBENZOFURAN-2-YL)-4,5-DIHYDRO-1H-IMIDAZOLE HCL,
2-Ethyl-2-(imidazolin-2-yl)-2,3-dihydrobenzofuran hydrochloride,
2-(2-ethyl-2,3-dihydro-2-benzofuranyl)-4,5-dihydro-1H-imidazolehydrochloride,
SR-01000075857,
Efaroxan HCl,
EU-0100521,
MLS002153473,
SPECTRUM2300218,
CHEMBL539313,
SCHEMBL1320556,
CTK8F9416,
DTXSID00474686,
Pharmakon1600-02300218,
Tox21_500521,
BN0204,
NSC759562,
AKOS022488640,
CCG-214022,
LP00521,
NSC-759562,
Efaroxan hydrochloride, >=98% (HPLC),
NCGC00093915-01,
NCGC00093915-02,
NCGC00093915-03,
NCGC00261206-01,
AS-53724,
SMR001230826,
FT-0732645,
E 3263,
C-54152,
SR-01000075857-1,
SR-01000075857-3,
SR-01000075857-6,
2-(2-Ethyl-2,3-dihydro-2-benzofuranyl)-4,5-dihydro-1H-imidazole hydrochloride,
2-(2-Ethyl-2,3-dihydro-benzofuran-2-yl)-4,5-dihydro-1H-imidazole hydrochloride,
Efaroxan,
CID11957548,
89197-32-0,